164,995 Shares in CVS Health Corporation $CVS Acquired by Callan Family Office LLC

Callan Family Office LLC purchased a new position in shares of CVS Health Corporation (NYSE:CVS) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 164,995 shares of the pharmacy operator’s stock, valued at approximately $17,069,000.

A number of other large investors also recently modified their holdings of CVS. Elevation Wealth Partners LLC increased its holdings in CVS Health by 41.8% in the second quarter. Elevation Wealth Partners LLC now owns 356 shares of the pharmacy operator’s stock valued at $37,000 after buying an additional 105 shares during the last quarter. Apella Capital LLC lifted its holdings in CVS Health by 1.7% during the 2nd quarter. Apella Capital LLC now owns 6,940 shares of the pharmacy operator’s stock worth $724,000 after buying an additional 117 shares during the last quarter. CYBER HORNET ETFs LLC boosted its position in shares of CVS Health by 4.1% during the 3rd quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator’s stock worth $259,000 after acquiring an additional 134 shares in the last quarter. Northwestern Mutual Investment Management Company LLC boosted its position in shares of CVS Health by 0.3% during the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 40,560 shares of the pharmacy operator’s stock worth $3,219,000 after acquiring an additional 136 shares in the last quarter. Finally, CoreCap Advisors LLC increased its holdings in shares of CVS Health by 4.2% in the 2nd quarter. CoreCap Advisors LLC now owns 3,481 shares of the pharmacy operator’s stock valued at $360,000 after acquiring an additional 139 shares during the last quarter. 80.66% of the stock is owned by hedge funds and other institutional investors.

CVS Health Trading Down 0.7%

CVS opened at $93.01 on Friday. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.74. CVS Health Corporation has a 52 week low of $69.51 and a 52 week high of $110.68. The business’s 50 day moving average is $102.02 and its two-hundred day moving average is $88.86. The firm has a market cap of $118.96 billion, a price-to-earnings ratio of 24.61, a price-to-earnings-growth ratio of 0.85 and a beta of 0.61.

CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.87 by $0.71. The business had revenue of $106.10 billion for the quarter, compared to analyst estimates of $100.03 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The company’s revenue for the quarter was up 7.3% compared to the same quarter last year. During the same period last year, the firm posted $1.81 earnings per share. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, research analysts predict that CVS Health Corporation will post 8.02 EPS for the current year.

CVS Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd were paid a $0.665 dividend. The ex-dividend date was Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.9%. CVS Health’s payout ratio is currently 70.37%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on CVS shares. Wall Street Zen upgraded CVS Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. DA Davidson increased their price target on shares of CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Barclays raised their price objective on shares of CVS Health from $106.00 to $108.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Sanford C. Bernstein boosted their price objective on shares of CVS Health from $94.00 to $106.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 12th. Finally, HSBC reiterated a “hold” rating and set a $103.00 price target on shares of CVS Health in a research note on Monday, July 6th. Twenty-two equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, CVS Health has an average rating of “Moderate Buy” and a consensus target price of $107.17.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.